Oxi4503, a novel vascular targeting agent: Effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate

Anticancer Research

Volumn 23, Issue 2 B, 2003, Pages 1433-1440

  Hua, Jianyi ^a   Sheng, Yezhou ^a   Pinney, Kevin G ^b   Garner, Charles M ^b   Kane, Robert R ^b   Prezioso, Joseph A ^c   Pettit, George R ^d   Chaplin, David J ^c   Edvardsen, Klaus ^a  

^a LUND UNIVERSITY   (Sweden)

^b BAYLOR UNIVERSITY   (United States)

^c Oxigene Inc   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Antitumor activity; Combretastatins; Vascular targeting

Indexed keywords

ANTINEOPLASTIC AGENT; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD FLOW; BLOOD FLOWMETRY; CANCER CONTROL; CANCER TRANSPLANTATION; CELL DEATH; CELL LOSS; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG TARGETING; FEMALE; FLUORESCENCE; FLUORESCENCE MICROSCOPY; HEMANGIOENDOTHELIOSARCOMA; HUMAN; HUMAN CELL; INJECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCID MOUSE; TUMOR CELL; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VASCULARIZATION;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; BREAST NEOPLASMS; DIPHOSPHATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCENT DYES; HEMANGIOENDOTHELIOMA; HUMANS; MALE; MICE; MICE, SCID; MICROSCOPY, FLUORESCENCE; MICROSPHERES; NEOVASCULARIZATION, PATHOLOGIC; REGIONAL BLOOD FLOW; STILBENES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0038576983     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Chaplin DJ, Pettit GR, Parkins CS and Hill SA: Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer 74 (Suppl. XXVII): S86-88, 1996.
2. Hill SA, Lonergan SJ, Denekamp J and Chaplin DJ: Vinca alkaloids: anti-vascular effects in a murine tumor. Eur J Cancer 29: 1320-1324, 1993.
3. Seed L, Slaughter D and Limarzi LR: Effect of colchicines on human carcinoma. Surgery 7: 696-709, 1940.
4. Lin CM, Singh SB, Chu PS, Dempcy RO, Schmidt JM, Pettit GR et al: Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure -activity study. Mol Pharmacol 34: 200-208, 1988.
5. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS and Garcia-Kendall D: Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45: 209211, 1989.
6. Woods JA, Hadfield JA, Pettit GR, Fox BW and McGown AT: The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer 71: 705-711, 1995.
7. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR and Chaplin DJ: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829-1834,1997.
8. Chaplin DJ, Pettit GR and Hill SA: Anti-vascular approaches to solid tumor therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 19: 189-195, 1999.
9. Grosios K, Holwell SE, McGown AT, Pettit GR and Bibby MC: In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81: 1318-1327, 1999.
10. Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE and Brindle KM: Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumor perfusion and energetic status. Br J Cancer 77: 1761-1767, 1998.
11. Beauregard DA, Hill SA, Chaplin DJ and Brindle KM: The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 61: 6811-6815, 2001.
12. Böhle AS, Sipos B, Kliche U and Dohrmann P: Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model. Ann Thorac Surg 71: 1657-1665, 2001.
13. Nelkin BD and Ball DW: Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep 8: 157-160, 2001.
14. Nabha SM, Mohammad RM, Wall NR, Dutcher JA., Salkini BM, Pettit GR et al: Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy. Anticancer Drugs 12: 57-63, 2001.
15. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR et al: Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59: 1626-1634, 1999.
16. Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B et al: Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumor vascular targeting activity in vivo. Anticancer Res 21(1A): 93-102, 2001.
17. Horsman MR, Ehrnrooth E, Ladekarl M and Overgaard J: The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys 42: 895-898, 1998.
18. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW et al: Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61: 6413-6422, 2001.
19. Landuyt W, Verdoes O, Darius DO, Drijkoningen M, Nuyts S, Theys J et al: Vascular targeting of solid tumors: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer 36: 1833-1843, 2000.
20. Griggs J, Brindle KM, Metcalfe JC, Hill SA, Smith GA, Beauregard DA et al: Potent antimetastatic activity of combretastatin-A4. Int J Oncol 19: 821-825, 2001.
21. Malcontenti-Wilson C, Muralldharan V, Skinner S, Christophi C, Sherris D and O'Brien PE: Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Clin Cancer Res 7: 1052-1060, 2001.
22. Landuyt W, Ahmed B, Nuyts S, Theys J, Op de Beeck M, Rijnders A et al: In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 49: 443-450, 2001.
23. Li L, Rojiani A and Siemann DW: Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 42: 899-903, 1998.
24. Horsman MR, Murata R, Breidahl T, Nielsen FU, Maxwell RJ, Stodkiled-Jorgensen H et al: Combretastatins novel vascular targeting drugs for improving anti-cancer therapy: Combretastatins and conventional therapy. Adv Exp Med Biol 476: 311-323, 2000.
25. Murata R, Siemann DW, Overgaard J and Horsman, MR: Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol 60: 155-161, 2001.
26. Murata R, Overgaard J and Horsman MR: Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int J Radiat Oncol Biol 51: 1018-1024, 2001.
27. Grosios K, Loadman PM, Swaine DJ, Pettit GR and Bibby MC: Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 20: 229-233, 2000.
28. Eikesdal HP, Schein BC, Mella O and Dahl O: The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. Int J Radiat Oncol Biol Phys 46: 645-652, 2000.
29. Eikesdal HP, Bjerkvig R, Mella O and Dahl O: Cornbretastatin A-4 and hyperthermia: a potent combination for the treatment of solid tumors. Radiother Oncol 60: 147-154, 2001.
30. Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R et al: Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate. Cancer Res 61: 4716-4722, 2001.
31. Pettit GR, Lippert JW 3rd: Antineoplastic agents 429 Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs. Anticancer Drug Des 15: 203-216, 2000.
32. Holwell SE, Cooper PA, Grosios K, Lippert JW 3rd, Pettit GR, Shnyder SD and Bibby MC: Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo antivascular effects in experimental turnouts. Anticancer Res 22(2A): 707-711, 2002.
33. Hill SA, Toze GM, Pettit GR and Chaplin DJ: Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi4503. Anticancer Res 22(3): 1453-1458, 2002.
34. Murata R, Overgaard J and Horsman MR: Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumor and normal tissues. Int J Radiat Biol 77: 195-204, 2001.
35. Boucher Y, Baxter LT and Jain RK: Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 50: 4478-4484, 1990.
36. Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
37. Harris AL: Hypoxia - a key regulatory factor in tumor growth. Nature Review (Cancer) 2: 38-47, 2002.
38. Ruoslahti E: Specialization of tumor vasculature. Nature Review (Cancer) 2: 83-90, 2002.